[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Article](https://github.com/mm80843/T3.5/tree/main/docs/Article/index.md) >> Individual ID:PBN__Article_245 

# __Contributions to the mitigation of the COVID-19 pandemic__

## Benefits listed in this article

* [Early detection of waning efficacy](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_145.md)
* [Enhanced surveillance and detection](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1184.md)
* [Reduced risk of reinfection](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1186.md)
* [Tailored protection for symptomatic and asymptomatic patients](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1185.md)

## DOI of the article

10.1093/cid/ciac033

## List of risks in an article

* [Disease severity in re-infected patients](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1888.md)
* [Inadequate vaccine efficacy](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1889.md)
* [Missing vaccination data](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1890.md)
* [Underreporting of infections](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1891.md)
* [Variation in protection against re-infections](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_586.md)

## Short summary of the article

This study examines the efficacy and duration of natural immunity against SARS-CoV-2 reinfection. The overall protection against reinfection was found to be 85.7%, suggesting that natural immunity provides significant defense against subsequent infections. The study also analyzed a subgroup of vaccinated individuals with previous infection, reporting similar protection against reinfections. However, there were limitations in terms of missing data on vaccination status and the need for additional information on infection rates in the vaccinated group. Additionally, the study highlights the importance of considering seroprevalence surveys and testing frequency when interpreting reinfection data. It also suggests that reinfections may have lower odds of hospitalization or death compared to primary infections, but cautions against drawing firm conclusions on disease severity. Furthermore, it proposes evaluating whether protection against reinfection differs based on symptoms at the initial infection. Overall, this research contributes to the understanding of natural immunity and its role in mitigating the COVID-19 pandemic.

## Summary of the article

The text is talking about a study on COVID-19 infections. It found that people who had previously been infected with COVID-19 and got vaccinated had a good protection against getting infected again. The study also mentioned that some people who got vaccinated were not fully vaccinated or their vaccination status was unclear. This means that more data is needed to understand how well the vaccine protects against reinfections. It's also important to consider that some people may have had COVID-19 but didn't know it because they didn't get tested. Overall, the study suggests that getting vaccinated, along with other preventive measures, can help fight against COVID-19.

## This article mentions these technologies

* [Comparative studies and data analysis technologies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1305.md)
* [Data completion and vaccination tracking technologies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1307.md)
* [Diagnostic testing technologies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1310.md)
* [Research and data analysis technologies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1308.md)
* [Serological testing technologies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1309.md)
* [Vaccine development and improvement technologies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1306.md)

## This article points to following mitigation

* [Data completion](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_3329.md)
* [Evaluation of symptoms](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_4529.md)
* [Lower testing frequency](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_4533.md)
* [Preventive and therapeutic measures](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_4532.md)
* [Seroprevalence surveys](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_4530.md)
* [Vaccination](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_4531.md)

## Title of the article

Contributions to the mitigation of the COVID-19 pandemic

## Year of publication

2022

